Thong Q. Le currently serves as Senior Managing Director and CEO of Accelerator Life Science Partners (ALSP), an early-stage life science accelerator and investment firm that creates and builds next-generation biotechnology companies centered on innovative science. Mr. Le has over 20 years of experience identifying, investing in, managing, and successfully exiting numerous seed and early-stage investments in the biotechnology sector. He has served as the founding CEO and director of numerous Accelerator Life Science Partners portfolio companies, including Petra Pharma (substantial acquisition by a global pharmaceutical company in May 2020), Rodeo Therapeutics (acquired by Amgen Inc. for up to $721M in March 2021), and Lodo Therapeutics (acquired by Zymergen in May 2021). He currently oversees the firm’s investments in ALSP ORCHID Acquisition Corporation I, KayoThera, Lydian Neurosciences, and Proniras Corporation, where he also serves as CEO and Director of each company. Mr. Le completed post-graduate studies at the Templeton College of Oxford University and received his A.B. cum laude in Government from Harvard University. He serves on the advisory board for the Alexandria Seed Capital Platform and on the boards of Acylin Therapeutics, Oerth Bio, and Ravenna Pharmaceuticals. He was previously named one of the region’s “40 Under 40” by the Puget Sound Business Journal.